Neurocrine Biosciences (NBIX) said Friday its board authorized a new share repurchase program allowing the company to buy back up to $500 million of its shares.
The company said the new authorization is in addition to the $300 million accelerated repurchase program launched in October 2024, which was completed in early February 2025.
Under the new authorization, the company said repurchases may occur at management's discretion through various methods, including open-market transactions, pre-set trading plans, privately negotiated deals, and accelerated share repurchases, all in line with securities laws.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.